Browse > Article
http://dx.doi.org/10.14374/HFS.2015.23.2.171

Effects of Sagan-tang and individual herbs on COPD Mice Model  

Han, Jong-Min (Division of Respiratory System, Dept. of Internal Medicine, College of Korean Medicine, Daejeon University)
Yang, Won-Kyung (Institute of Traditional Medicine and Bioscience, Daejeon University)
Kim, Seung-Hyeong (Institute of Traditional Medicine and Bioscience, Daejeon University)
Park, Yang-Chun (Division of Respiratory System, Dept. of Internal Medicine, College of Korean Medicine, Daejeon University)
Publication Information
Herbal Formula Science / v.23, no.2, 2015 , pp. 171-187 More about this Journal
Abstract
Objective This study aimed to evaluate the effects of Sagan-tang (SGT) on COPD mouse model. Methods The study was carried out by two ways (in vitro, in vivo). In vitro RAW264.7 cells (mouse macrophage) were used and analysed by flow cytometry, ELISA, Western blot. In vivo LPS and CSS challenged mice were used and its BALF had been analysed by cytospin image, FACS, ELISA, lung tissue by real-time PCR. Results In vitro, SGT maintained 80-100% rate of viablilty on 10 ~ 500 ㎍/㎖ concentration. In ELISA analysis with RAW264.7 cells, SGT significantly decreased NO over 30 ㎍/㎖. In flow cytometry, SGT 100 ㎍/㎖ dosage group displayed a tendency for decrease ROS. In Western blot analysis, SGT 100 ㎍/㎖ dosage group decreased NF-κB. In ELISA analysis, SGT significantly decreased TNF-α, IL-6 over 200 ㎍/㎖. In vivo SGT 200 ㎎/㎏ dosage group, application of SGT significantly decreased increase of neutrophils, TNF-α, IL-6 in BALF, muc5AC, TGF-β, TNF-α, expression of mRNA in lung tissue and histological lung injury. Conclusion This Study suggests usability of SGT for COPD patients by controlling lung tissue injury.
Keywords
Sagan-tang (shè gā n-tā ng); chronic obstructive pulmonary disease; cigarette smoke solution;
Citations & Related Records
Times Cited By KSCI : 7  (Citation Analysis)
연도 인용수 순위
1 Lee ES, Han JM, Kim MH, Namgung U, Yeo Y, Park YC. Effects of inhalable microparticles of Socheongryong-tang on chronic obstructive pulmonary disease in a mouse model. J Korean Med. 2013;34(3):54-68.   DOI
2 Lee ES, Yang SY, Kim MH, Namgung U, Park YC. Effects of root of liriope spicata on LPS-induced lung injury. Korean J Oriental Physiology & Pathology 2011;25(4):641-9.
3 Zhao ji (趙佶). Shengjizonglu (聖濟總錄)(4). Seoul: Euisungdang; 1993, p2858-71.
4 The korean academy of tuberculosis and respiratory disease. Pneumonology. Seoul: Koonja; 2007, p301-8.
5 Jung YM, Lee HY. Chronic Obstructive Pulmonary Disease in Korea: Prevalence, Risk Factors, and Quality of Life. J Korean Acad Nurs 2011;41(2):149-56.   DOI
6 Statistics Korea. Survey of Teenagers accessibility at harmful environment. 2008-2012;[4screens] Available at: URL: http://www.kostat.go.kr. Accessed Nov 1, 2014.
7 Choo HK. A Study of the Knowledge and Attitudes of Middle School Students regarding Smoking. Dissertation (master's degreee). Hanyang university postgraduate school. 2009, p.1-80.
8 Ministry of Health & Welfare. 2012 national nutrition survey. 2013;[5screens] Available at: URL: https://knhanes.cdc.go.kr. Accessed Nov 1, 2014.
9 Diaz-Guzman E, Mannino DM. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):7-16.   DOI
10 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. 2014[102screens] Available at: URL: http://www.goldcopd.org. Accessed Nov 1, 2014.
11 Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004;364(9438):985-96.   DOI
12 Jung SK, Jung HJ, Kim JD, Choi HY, Park MY, Park YC. Pye-gye-nae-gwa-hak. Seoul: Nado; 2011, p510-11.
13 Ministry of food and drug safety. Mensuration pernicious ingredients of cigarette type depressant for smoking guideline revision. 2012;[16screens] Available at: URL: http://www.mfds.go.kr. Accessed Nov 1, 2014.
14 Lee JG, Yang SY, Kim MH, Namgung U, Park YC. Protective effects of Socheongryong-tang on elastase-induced lung injury. J Korean Oriental Med. 2011;32(4 ):83-99.
15 Kim HW, Yang SY, Kim MH, Namgung U, Park YC. Protective effects of Maekmundong-tang on elastase induced lung injury. J Korean Oriental Med. 2011;32(2):63-78.
16 Kim Y, Yang SY, Kim MH, Namgung U, Park YC. Effects of Saengmaekcheongpye-eum on LPS-induced COPD model. Korean J Orient. Int. Med. 2011;32(2):217-31.
17 Lee H, Kim Y, Kim HJ, Park S, Jang YP, Jung S, Jung H, Bae H. Herbal Formula, PM014, Attenuates Lung Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease. Evid Based Complement Alternat Med. 2012;2012:769830.
18 Park YC, Jin MR, Kim SH, Kim MH, Namgung U, Yeo Y. Effects of inhalable microparticle of flower of Lonicera japonica in a mouse model of COPD. J Ethnopharmacol. 2014;151(1):123-30.   DOI
19 Jung KH, Lee KS, Kim YE, Park SJ, Hong MC, Shin MK et al. Lonicerae Flos Inhibits Cigarette-induced Lung inflammatory Response in Animal Model of Chronic Obstructive Pulmonary Disease. J Korean Med. 2013;34(2):10-9.   DOI
20 Lee DJ. effects of Lonicera japonica on the murine model of Chronic obstructive pulmonary disease. Dissertation (doctor's degreee) Kyunghee postgraduate school 2009, p.1-34.
21 Park DH, Jung SK, Jung HJ. The effects of bee venom on lipopolysaccharide (LPS)-induced Chronic Obstructive Pulmonary Disease (COPD). Korean J Orient. Int. Med. 2011;32(2):203-16.
22 Rom O, Avezov K, Aizenbud D, Reznick AZ. Cigarette smoking and inflammation revisited. Respir Physiol Neurobiol. 2013;187(1):5-10.   DOI
23 Schaberg T, Haller H, Rau M, Kaiser D, Fassbender M, Lode H. Superoxide anion release induced by platelet-activating factor is increased in human alveolar macrophages from smokers. Eur Respir J 1992;5(4):387-93.
24 Cartin A, Crystal RG. Oxidants, antioxidants and the pathogenesis of emphysema. Eur Respir Dis Suppl 1985;139:7-17.
25 Laurent P, Janoff A, Kagan HM. Cigarette smoke blocks cross linking of elastin in vitro. Am Rev Respir 1983;127(2):189-92.
26 Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153(2):530-4.   DOI
27 Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158(4):1277-85.   DOI
28 Mizutani N. Fuchikami J. Takahashi M. Nabe T. Yoshino S. Kohno S. Pulmonary emphysema induced by cigarette smoke solution and lipopolysaccharide in guinea pigs. Biol Pharm Bull. 2009;32(9):1559-64.   DOI
29 Stănescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax. 1996;51(3):267-71.   DOI
30 Imai K, Mercer BA, Schulman LL, Sonett JR, D'Armiento JM. Correlation of lung surface area to apoptosis and proliferation in human emphysema. Eur Respir J. 2005;25(2):250-8.   DOI
31 Wang G, Xu Z, Wang R, Al-Hijji M, Salit J, Strulovici-Barel Y et al. Genes associated with MUC5AC expression in small airway epithelium of human smokers and nonsmokers. BMC Med Genomics 2012;5(1): 21. doi:10.1186/1755-8794-5-21.   DOI
32 Pittet D, Harbarth S, Suter PM, Reinhart K, Leighton A, Barker C et al. Impact of immunomodulating therapy on morbidity in patients with severe sepsis. Am J Respir Crit Care Med. 1999;160(3):852-7.   DOI
33 Kemeny DM, Vyas B, Vukmanovic-Stejic M, Thomas MJ, Noble A, Loh LC et al. CD8(+) T cell subsets and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(5 Pt 2):S33-7.   DOI
34 Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(2):349-55.   DOI
35 Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114-20.   DOI
36 Borchers MT, Carty MP, Leikauf GD. Regulation of human airway mucins by acrolein and inflammatory mediators. Am J Physiol. 1999;276(4 Pt 1):549-55.
37 Lukacs NW, Hogaboam CM, Kunkel SL. Chemokines and their receptors in chronic pulmonary disease. Curr Drug Targets Inflamm Allergy. 2005;4(3):313-7.   DOI
38 Traves SL, Culpitt SV, Russell REK, Barnes PJ, Donnelly LE. Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD. Thorax 2002;57(7):590-595.   DOI
39 Guzman K, Gray TE, Yoon JH, Nettesheim P. Quantitation of mucin RNA by PCR reveals induction of both MUC2 and MUC5AC mRNA levels by retinoids. Am J Physiol 1996; 271(6 Pt 1):1023-8.
40 Di Stefano A, Caramori G, Oates T, Capelli A, Lusuardi M, Ginemmi I et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 2002;20(3):556-63.   DOI
41 Barnes PJ, Karin M. Nuclear factor- (kappa) B-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336(15):1066-71.   DOI
42 Lambrecht BN, Prins JB, Hoogsteden HC. Lung dendritic cells and host immunity to infection. Eur Respir J 2001;18(4):692-704.
43 Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118(11):3546-56.   DOI